Article
Endocrinology & Metabolism
Sabrina Chiloiro, Antonio Bianchi, Antonella Giampietro, Alfredo Pontecorvi, Gerald Raverot, Laura De Marinis
Summary: This review provides an overview of the second-line therapies for acromegaly, summarizing the evidence on clinical, molecular, and morphological aspects that can predict the response to these treatments and advocating for a patient-tailored therapeutic approach in clinical practice.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Antonella Giampietro, Sara Menotti, Sabrina Chiloiro, Alfredo Pontecorvi, Laura De Marinis, Antonio Bianchi
Summary: This study reports three cases of resistant acromegaly treated with a de-escalation approach using pasireotide LAR. The results showed that de-escalation treatment with pasireotide LAR may allow a greater proportion of patients to achieve control of acromegaly, especially in clinically aggressive cases. Although there may be a risk of hyperglycemia, it can be controlled with oral antidiabetic medications.
Article
Multidisciplinary Sciences
Eva Revilla-Lopez, Cristina Berastegui, Alejandra Mendez, Berta Saez-Gimenez, Victoria Ruiz de Miguel, Manuel Lopez-Meseguer, Victor Monforte, Carlos Bravo, Miguel Angel Pujana, Maria Antonia Ramon, Susana Gomez-Olles, Antonio Roman
Summary: This study found that sirolimus treatment had a positive long-term effect on most LAM patients, with 59% showing a positive response, 30% showing a partial response, and 11% showing a negative response after 5 years of treatment.
SCIENTIFIC REPORTS
(2021)
Article
Endocrinology & Metabolism
Adriana P. Kuker, Wei Shen, Zhezhen Jin, Simran Singh, Jun Chen, Jeffrey N. Bruce, Pamela U. Freda
Summary: Long-term pegvisomant therapy leads to increases in visceral and subcutaneous adipose tissue mass, stable skeletal muscle mass, and improvements in glucose metabolism.
JOURNAL OF THE ENDOCRINE SOCIETY
(2021)
Article
Endocrinology & Metabolism
Thierry Brue, Philippe Chanson, Patrice Rodien, Brigitte Delemer, Delphine Drui, Lucile Marie, Laurene Juban, Lara Salvi, Robin Henocque, Gerald Raverot
Summary: The study aimed to estimate the cost-utility of second-line pharmacological treatments in acromegaly patients.
The incremental cost-utility ratios for pasireotide, pegvisomant, and pegvisomant + FGSA were estimated, showing pasireotide to be the least cost-efficient treatment option.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Sabrina Chiloiro, Antonella Giampietro, Federica Mirra, Federico Donfrancesco, Tommaso Tartaglione, Pier Paolo Mattogno, Flavia Angelini, Lauretti Liverana, Marco Gessi, Anile Carmelo, Guido Rindi, Andrea Giustina, Maria Fleseriu, Alfredo Pontecorvi, Laura De Marinis, Antonio Bianchi
Summary: The study investigated predictors of response to Pegvisomant and Pasireotide LAR in acromegaly patients, finding that factors such as tumor extension, Ki67-Li levels, and IGF-I levels may impact treatment efficacy.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Peter Wolf, Sylvie Salenave, Emmanuel Durand, Jacques Young, Peter Kamenicky, Philippe Chanson, Luigi Maione
Summary: The treatment of acromegaly strongly affects body composition until biochemical disease remission, characterized by an increase in fat mass and a decrease in lean mass. These changes are closely associated with the normalization of IGF-I and are independent of individual therapy.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2022)
Article
Endocrinology & Metabolism
E. Sala, G. Carosi, G. Del Sindaco, R. Mungari, A. Cremaschi, A. L. Serban, C. L. Ronchi, E. Ferrante, M. Arosio, G. Mantovani
Summary: A subset of well-controlled acromegalic patients can successfully withdraw from SAs, challenging the concept that medical therapy is a lifelong requirement.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
(2021)
Article
Endocrinology & Metabolism
Roberto Salvatori, Pietro Maffei, Susan M. Webb, Thierry Brue, Jane Loftus, Srinivas Rao Valluri, Roy Gomez, Michael P. Wajnrajch, Maria Fleseriu
Summary: Overall, patients treated with PEGV had small improvements in PASQ. While IGF-I normalization increased with PEGV treatment, IGF-I control had no effects on PASQ and AcroQoL scores.
Article
Oncology
Masaru Takagi, Yusuke Demizu, Osamu Fujii, Kazuki Terashima, Yasue Niwa, Takashi Daimon, Sunao Tokumaru, Nobukazu Fuwa, Masato Hareyama, Tomoaki Okimoto
Summary: Despite controversy, proton therapy has been used to treat localized prostate cancer for the past two decades. A retrospective observational study was conducted on 2021 patients from 2003 to 2014, showing favorable biochemical control and low incidence of late toxicities, supporting the feasibility of prospective clinical trials. Risk groups defined by the National Comprehensive Cancer Network guidelines seem useful in classifying patients with localized prostate cancer. Our findings suggest the importance of considering the patient's age in developing a treatment strategy.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Endocrinology & Metabolism
Emmanuelle Kuhn, Philippe Caron, Brigitte Delemer, Isabelle Raingeard, Herve Lefebvre, Gerald Raverot, Christine Cortet-Rudelli, Rachel Desailloud, Clementine Geffroy, Robin Henocque, Yves Brault, Thierry Brue, Philippe Chanson
Summary: The study aimed to define the medical reasons for treating patients with Pegvisomant (PEG) as monotherapy or combined therapy with somatostatin analogs (SAs). Results showed different patterns of treatment based on patient characteristics and response to therapy, with a focus on tumor concern and ease of normalizing IGF-I levels. Overall, the prospect of reducing PEG injection frequency favored the choice of combined therapy in certain cases.
Article
Endocrinology & Metabolism
R. Pirchio, R. S. Auriemma, M. E. Montini, A. Vergura, R. Pivonello, A. Colao
Summary: This study investigated the effects of 10-year PEG treatment on disease control, maximal tumor diameter, and metabolic profile in patients with acromegaly resistant to somatostatin analogues. The results showed that after 10 years, 91% of patients achieved full disease control and 37% had a significant decrease in tumor diameter. Early initiation of PEG treatment was associated with improved glucose and insulin metabolism.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
(2023)
Article
Endocrinology & Metabolism
Monica Gadelha, Nelma Veronica Marques, Christhiane Fialho, Cristiane Scaf, Elisa Lamback, Ximene Antunes, Erica Santos, Jaqueline Magalhaes, Luiz Eduardo Wildemberg
Summary: This study retrospectively analyzed the long-term efficacy and safety of Pasireotide, a somatostatin receptor ligand, in the treatment of acromegaly patients. The results showed that Pasireotide provided clinical benefit and was well tolerated for over 11 years of treatment in acromegaly patients.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Oncology
Gi-June Min, Young-Woo Jeon, Tong Yoon Kim, Dae Hun Kwag, Jong Hyuk Lee, Joon Yeop Lee, Sung-Soo Park, Silvia Park, Jae-Ho Yoon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Hee-Je Kim, Chang-Ki Min, Jong Wook Lee, Seok-Goo Cho
Summary: This study retrospectively analyzed the clinical characteristics, treatment modalities, and prognostic factors of 88 patients with Castleman disease. The results showed that surgical resection of a solitary mass was associated with favorable outcomes in patients with unicentric Castleman disease, while older age and splenomegaly were identified as independent prognostic factors in patients with multicentric Castleman disease.
FRONTIERS IN ONCOLOGY
(2022)
Review
Medicine, General & Internal
Juan Chen, Zhigao Xiang, Zhuo Zhang, Yan Yang, Kai Shu, Ting Lei
Summary: Acromegaly is characterized by overproduction of growth hormone and accompanying insulin-like growth factor-1, leading to somatic burden and psychosocial changes. Studies have shown that patients with acromegaly often experience cognitive impairment and neuropsychological issues. This review outlines the impact of disease progression, treatment modalities, and comorbidities on cognitive function and the mechanisms of cognitive impairment in acromegaly patients.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Claire E. Higham, Viktoria Chatzimavridou-Grigoriadou, Cheryl T. Fitzgerald, Peter J. Trainer, Alexander M. M. Eggermont, Paul Lorigan
EUROPEAN JOURNAL OF CANCER
(2020)
Article
Oncology
Tim Cooksley, Tom Knight, Avinash Gupta, Claire Higham, Paul Lorigan, Safwaan Adam
SUPPORTIVE CARE IN CANCER
(2020)
Letter
Oncology
Sacha J. Howell, Brian Keevil, Claire Higham, Laura J. Owen, Phillip J. Monaghan
EUROPEAN JOURNAL OF CANCER
(2020)
Article
Endocrinology & Metabolism
Salma R. Ali, Jillian Bryce, Houra Haghpanahan, James D. Lewsey, Li En Tan, Navoda Atapattu, Niels H. Birkebaek, Oliver Blankenstein, Uta Neumann, Antonio Balsamo, Rita Ortolano, Walter Bonfig, Hedi L. Claahsen-van der Grinten, Martine Cools, Eduardo Correa Costa, Feyza Darendeliler, Sukran Poyrazoglu, Heba Elsedfy, Martijn J. J. Finken, Christa E. Fluck, Evelien Gevers, Marta Korbonits, Guilherme Guaragna-Filho, Tulay Guran, Ayla Guven, Sabine E. Hannema, Claire Higham, Ieuan A. Hughes, Rieko Tadokoro-Cuccaro, Ajay Thankamony, Violeta Iotova, Nils P. Krone, Ruth Krone, Corina Lichiardopol, Andrea Luczay, Berenice B. Mendonca, Tania A. S. S. Bachega, Mirela C. Miranda, Tatjana Milenkovic, Klaus Mohnike, Anna Nordenstrom, Silvia Einaudi, Hetty van der Kamp, Ana Vieites, Liat de Vries, Richard J. M. Ross, S. Faisal Ahmed
Summary: The study analyzed data from children with classic 21-hydroxylase deficiency CAH from 34 centers in 18 countries, finding that the number of SDE per patient-year was higher in Low or Middle Income Countries. Infectious illness was the most common precipitating event for both SDE and AC.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Hematology
Stephen Booth, Hannah Plaschkes, Amy A. Kirkwood, Adam Gibb, Patrick Horgan, Claire Higham, Joanna M. Oladipo, Joe Browning, Usman Khan, Bing Tseu, Lucia Chen, John Willan, Julia Wolf, Arief Gunawan, Paul Fields, Tim Ebsworth, Robert Lown, Dominic Gordon-Walker, Nimish Shah, Kim M. Linton, Graham P. Collins, Jaimal Kothari, Catherine Hildyard, Toby A. Eyre
Article
Endocrinology & Metabolism
Irina Bacila, Nicole Freeman, Eleni Daniel, Marija Sandrk, Jillian Bryce, Salma Rashid Ali, Zehra Yavas Abali, Navoda Atapattu, Tania A. Bachega, Antonio Balsamo, Niels Birkebaek, Oliver Blankenstein, Walter Bonfig, Martine Cools, Eduardo Correa Costa, Feyza Darendeliler, Silvia Einaudi, Heba Hassan Elsedfy, Martijn Finken, Evelien Gevers, Hedi L. Claahsen-van der Grinten, Tulay Guran, Ayla Guven, Sabine E. Hannema, Claire E. Higham, Violeta Iotova, Hetty J. van der Kamp, Marta Korbonits, Ruth E. Krone, Corina Lichiardopol, Andrea Luczay, Berenice Bilharinho Mendonca, Tatjana Milenkovic, Mirela C. Miranda, Klaus Mohnike, Uta Neumann, Rita Ortolano, Sukran Poyrazoglu, Ajay Thankamony, Jeremy W. Tomlinson, Ana Vieites, Liat de Vries, S. Faisal Ahmed, Richard J. Ross, Nils P. Krone
Summary: Data from the I-CAH Registry reveals international variations in hormone replacement therapy for CAH patients, with a tendency towards high-dose treatment in children.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Victoria Chatzimavridou-Grigoriadou, Sami Al-Othman, Georg Brabant, Angelos Kyriacou, Jennifer King, Fiona Blackhall, Peter J. Trainer, Claire E. Higham
Summary: In a retrospective evaluation, low-dose tolvaptan was shown to effectively correct hyponatremia due to SIAD in cancer patients, but a significant proportion experienced over-rapid correction, emphasizing the need to avoid the risk of over-rapid correction.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Yi Yuen Wang, Mueez Waqar, Ahmed Abou-Zeid, Tara Kearney, Carmela Caputo, Julian Davis, Peter Trainer, Claire Higham, Federico Roncaroli, Kanna K. Gnanalingham
Summary: Early post-operative basal GH and GH nadir on OGTT are reliable predictors of long-term disease remission and can guide patients for early surgical re-exploration for residual disease, despite the increased risk of hypopituitarism.
NEUROENDOCRINOLOGY
(2022)
Review
Endocrinology & Metabolism
Margaret C. S. Boguszewski, Adriane A. Cardoso-Demartini, Cesar Luiz Boguszewski, Wassim Chemaitilly, Claire E. Higham, Gudmundur Johannsson, Kevin C. J. Yuen
Summary: The safety of GH replacement therapy in survivors of cancer and brain tumors remains debated, with conflicting results from studies, especially in different age groups. While GH replacement therapy is considered relatively safe in individuals with non-functioning brain tumors, the risk versus benefit profile in other patients remains unclear.
Article
Endocrinology & Metabolism
Jenneke E. van Atteveld, Renee L. Mulder, Marry M. van den Heuvel-Eibrink, Melissa M. Hudson, Leontien C. M. Kremer, Roderick Skinner, W. Hamish Wallace, Louis S. Constine, Claire E. Higham, Sue C. Kaste, Riitta Niinimaki, Sogol Mostoufi-Moab, Nathalie Alos, Danilo Fintini, Kimberly J. Templeton, Leanne M. Ward, Eva Frey, Roberto Franceschi, Vesna Pavasovic, Seth E. Karol, Nadia L. Amin, Lynda M. Vrooman, Arja Harila-Saari, Charlotte Demoor-Goldschmidt, Robert D. Murray, Edit Bardi, Maarten H. Lequin, Maria Felicia Faienza, Olga Zaikova, Claire Berger, Stefano Mora, Kirsten K. Ness, Sebastian J. C. M. M. Neggers, Saskia M. F. Pluijm, Jill H. Simmons, Natascia Di Iorgi
Summary: Childhood, adolescent, and young adult cancer survivors are at increased risk of reduced bone mineral density, and guidelines for bone mineral density surveillance are important for timely diagnosis and treatment. Current discordances in guidelines highlight the need for international harmonisation to provide evidence-based care for survivors.
LANCET DIABETES & ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Claire Higham, Bo Abrahamsen
Summary: Hormonal regulation plays a critical role in determining bone mass in humans, with both skeletal growth and bone loss being controlled by endocrine factors. This article explores the impact of diabetes and disorders related to thyroid, parathyroid, sex steroids, and growth hormones on bone mass and fracture risk. It provides evidence for current management strategies and highlights areas for future research.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Editorial Material
Endocrinology & Metabolism
Judith Gebauer, Claire E. Higham
ENDOCRINE CONNECTIONS
(2022)
Article
Endocrinology & Metabolism
Victoria Chatzimavridou-Grigoriadou, Lisa H. Barraclough, Rohit Kochhar, Lucy Buckley, Nooreen Alam, Claire E. Higham
Summary: A retrospective study assessed bone mineral density and fracture risk in 39 patients who received pelvic radiotherapy, finding that most patients did not have osteoporosis at the time of radiotherapy-related insufficiency fractures (RRIFs). However, low bone mineral density may be a potential risk factor for fractures. Further studies are needed to understand the predictive value of bone mineral density.
ENDOCRINE CONNECTIONS
(2023)
Article
Oncology
R. Berman, A. Davies, T. Cooksley, R. Gralla, L. Carter, E. Darlington, F. Scotte, C. Higham